三氧化二砷对皮肤T细胞淋巴瘤Hut-78细胞株PML异构体及端粒酶逆转录酶表达影响的研究
|
摘要
目的：通过检测不同浓度三氧化二砷(ATO)对人皮肤T细胞淋巴瘤Hut-78细胞株的诱导凋亡作用、细胞周期及hTERT、PML、PML-Ⅰ、PML-Ⅳ和PML-V基因表达的影响,探讨上述基因在ATO诱导人皮肽T细胞淋巴瘤凋亡过程中的作用及可能机制。
方法：本课题采用PI单标记流式细胞术检测不同浓度的ATO,作用不同时间后,对人皮肤T细胞淋巴瘤Hut-78细胞株的诱导凋亡作用及对细胞周期的影响;采用RT-PCR方法检测不同浓度的ATO,作用不同时间后,对人皮肤T细胞淋巴瘤Hut-78细胞株hTERT、PML、PML-Ⅰ、PML-Ⅳ及PML-Ⅴ基因表达变化的影响。
结果：1、以2-10μmol/L浓度的ATO分别干预Hut-78细胞24、48、72小时,流式细胞仪分析各期细胞占细胞周期的比例及细胞凋亡(坏死)比率,结果示ATO干预后被阻滞于G2/M期的细胞随着ATO作用时间及浓度的增加比例逐渐增加,10μmol/L作用72小时时G2/M期比例最高,随药物浓度的增加及作用时间延长,Hut-78细胞的凋亡(坏死)比率逐渐增加；2、在ATO 2、5、10μmol/L三组浓度的作用下,用RT-PCR方法检测不同作用时间下Hut-78细胞hTERT、PML、PML-Ⅰ、PML-Ⅳ及PML-Ⅴ基因表达水平,结果示：(1)随着ATO浓度和作用时间的增加,hTERT mRNA的表达水平逐渐降低；(2)在不同浓度ATO作用48 h后PML的表达增加至最高,从48h至72h则逐渐降低；(3)在2umol/L 10umol/L和的ATO作用下,随着作用时间的延长,PML-I的表达逐渐增加；在对照组和5umol/L的ATO作用下,从24h至48h之间,随着时间延长,表达逐渐减少,而从48h至72h之间,则随着时间延长,表达逐渐增加；(4)在不同浓度ATO作用后,在24h至48h之间,随着时间延长,PML-IV的表达逐渐增加,在48至72h之间,随着时间延长,表达逐渐减低；(5)在对照组和2umol/L的ATO作用后,随着时间延长,PML-V的表达无明显变化；在5umol/L和10umol/L的ATO作用后,随着时间延长,表达逐渐增加,其中10umol/L的ATO作用后,PML-V表达量的增加趋势最大；3、PML-Ⅳ表达与hTERT基因的表达之间无相关性。
结论：1、在一定浓度范围内,ATO对Hut-78细胞存在增殖抑制作用,其增殖抑制作用在一定程度上可能与下调hTERT的表达有关；2、ATO可诱导Hut-78细胞发生凋亡,凋亡主要发生在G2/M期,其凋亡作用可能与PML、PML-I及PML-IV的表达增高及下调端粒酶活性有关；3、ATO对Hut-78细胞的诱导凋亡作用呈显著的时间一剂量依赖性；4、不同浓度范围的ATO对Hut-78细胞PML-V基因的表达影响不同,推测]PML-V只有在药物强应激情况下,表达才会激增。
Objective:To investigate the possible function and mechanism of the genes, such as Promyelocytic Leukemia, Promyelocytic Leukemia isoform I, Promyelocytic Leukemia isoformⅣ, Promyelocytic Leukemia isoform V and human telomerase reverse transcriptase, in Arsenic Trioxide on cutaneous T cell lymphoma cell line Hut-78 cells by detecting the apoptosis, effects of cell cycles and expression of these genes in cutaneous T-cell lymphoma cell line Hut-78 which was treated with Arsenic Trioxide of different concentrations.
Methods:The effect of Arsenic Trioxide in different concentrations and for different duration of time on apoptosis and cell cycles of hut-78 cells were analyzed by Flow cytometry with PI staining. The transcription level changes of hTERT, PML, PML-I, PML-Ⅳand PML-Ⅴgenes were detected by the reverse transcriptase-polymerase chain reaction (RT-PCR)
Results:1. Hut-78 cells were treated with the concentration range of 2-10μmol/L of ATO respectively for 24 h,48h and 72h. Then cell cycle, apoptosis and necrosis were measured by flow cytometry with PI staining. The results showed that, the ratio of G2/M phase of Hut-78 cells that was treated with Arsenic Trioxide was increased. When the Hut-78 cells were treated with 10μmol/L Arsenic Trioxide for 72 hours, the highest percentage of G2/M phase was detected. With the increasing of concentration and extending of action time, the rate of apoptosis and necrosis of Hut-78 cells was gradually increased; 2.The expressions of hTERT, PML, PML-Ⅰ, PML-Ⅳand PML-Ⅴgenes in Hut-78 cells treated with Arsenic Trioxide in different concentrations for different action time were detected by RT-PCR.The results show that:(1) The expression of hTERT mRNA gradually decreased with the concentration of ATO increasing and acting time extending; (2) After treated with ATO in different concentrations after 48h, the transcription level of PML reached a maximum value, which was gradually decreased from 48h to 72h; (3) With prolonging treatment with 2umol/L and 10umol/L ATO respectively,the transcription level of PML-Ⅰwas gradually increased,When the concentration of ATO is 0 umol/L and 5 umol/L respectively,with prolonging treatment,the transcription level was gradually decreased from 24h to 48h,while that was gradually increased from 48h to 72h; (4) With ATO in different concentration,the transcription level of PML-Ⅳwas gradually increased from 24h to 48h with the acting time extending,while that was gradually decreased from 48h to 72h; (5) When the concentration of ATO is 0 umol/L and 2 umol/L respectively,with prolonging treatment,The expression of PML-Ⅴdid not change significantly.When the concentration of ATO was 5 umol/L and 10 umol/L respectively, with prolonging treatment, the transcription level was gradually increased; And at the dosage of 10 umol/L the increased trend of the transcription level was the most significant; 3. There was no correlation between the expression level of PML-IVand hTERT.
Conclusion:1.Arsenic trioxide can inhibit the proliferation of Hut-78 cells in a certain range of concentrations, which may be related to the decreasement in the transcription level of hTERT to some extent; 2.ATO can induce apoptosis of Hut-78 cells. And apoptosis occurs mainly in G2/M phase, which may be related to PML, PML-Ⅰand PML-Ⅳincreased and decreased the expression of telomerase activity; 3.ATO can induce apoptosis of Hut-78 cells, which is dependent on time and dose; 4.The expression of PML-Ⅴwas different with ATO in different concentrations, we speculated that the expression level of PML-Ⅴcould remarkably increase only in the strong stress caused by drug.
方法：本课题采用PI单标记流式细胞术检测不同浓度的ATO,作用不同时间后,对人皮肤T细胞淋巴瘤Hut-78细胞株的诱导凋亡作用及对细胞周期的影响;采用RT-PCR方法检测不同浓度的ATO,作用不同时间后,对人皮肤T细胞淋巴瘤Hut-78细胞株hTERT、PML、PML-Ⅰ、PML-Ⅳ及PML-Ⅴ基因表达变化的影响。
结果：1、以2-10μmol/L浓度的ATO分别干预Hut-78细胞24、48、72小时,流式细胞仪分析各期细胞占细胞周期的比例及细胞凋亡(坏死)比率,结果示ATO干预后被阻滞于G2/M期的细胞随着ATO作用时间及浓度的增加比例逐渐增加,10μmol/L作用72小时时G2/M期比例最高,随药物浓度的增加及作用时间延长,Hut-78细胞的凋亡(坏死)比率逐渐增加；2、在ATO 2、5、10μmol/L三组浓度的作用下,用RT-PCR方法检测不同作用时间下Hut-78细胞hTERT、PML、PML-Ⅰ、PML-Ⅳ及PML-Ⅴ基因表达水平,结果示：(1)随着ATO浓度和作用时间的增加,hTERT mRNA的表达水平逐渐降低；(2)在不同浓度ATO作用48 h后PML的表达增加至最高,从48h至72h则逐渐降低；(3)在2umol/L 10umol/L和的ATO作用下,随着作用时间的延长,PML-I的表达逐渐增加；在对照组和5umol/L的ATO作用下,从24h至48h之间,随着时间延长,表达逐渐减少,而从48h至72h之间,则随着时间延长,表达逐渐增加；(4)在不同浓度ATO作用后,在24h至48h之间,随着时间延长,PML-IV的表达逐渐增加,在48至72h之间,随着时间延长,表达逐渐减低；(5)在对照组和2umol/L的ATO作用后,随着时间延长,PML-V的表达无明显变化；在5umol/L和10umol/L的ATO作用后,随着时间延长,表达逐渐增加,其中10umol/L的ATO作用后,PML-V表达量的增加趋势最大；3、PML-Ⅳ表达与hTERT基因的表达之间无相关性。
结论：1、在一定浓度范围内,ATO对Hut-78细胞存在增殖抑制作用,其增殖抑制作用在一定程度上可能与下调hTERT的表达有关；2、ATO可诱导Hut-78细胞发生凋亡,凋亡主要发生在G2/M期,其凋亡作用可能与PML、PML-I及PML-IV的表达增高及下调端粒酶活性有关；3、ATO对Hut-78细胞的诱导凋亡作用呈显著的时间一剂量依赖性；4、不同浓度范围的ATO对Hut-78细胞PML-V基因的表达影响不同,推测]PML-V只有在药物强应激情况下,表达才会激增。
Objective:To investigate the possible function and mechanism of the genes, such as Promyelocytic Leukemia, Promyelocytic Leukemia isoform I, Promyelocytic Leukemia isoformⅣ, Promyelocytic Leukemia isoform V and human telomerase reverse transcriptase, in Arsenic Trioxide on cutaneous T cell lymphoma cell line Hut-78 cells by detecting the apoptosis, effects of cell cycles and expression of these genes in cutaneous T-cell lymphoma cell line Hut-78 which was treated with Arsenic Trioxide of different concentrations.
Methods:The effect of Arsenic Trioxide in different concentrations and for different duration of time on apoptosis and cell cycles of hut-78 cells were analyzed by Flow cytometry with PI staining. The transcription level changes of hTERT, PML, PML-I, PML-Ⅳand PML-Ⅴgenes were detected by the reverse transcriptase-polymerase chain reaction (RT-PCR)
Results:1. Hut-78 cells were treated with the concentration range of 2-10μmol/L of ATO respectively for 24 h,48h and 72h. Then cell cycle, apoptosis and necrosis were measured by flow cytometry with PI staining. The results showed that, the ratio of G2/M phase of Hut-78 cells that was treated with Arsenic Trioxide was increased. When the Hut-78 cells were treated with 10μmol/L Arsenic Trioxide for 72 hours, the highest percentage of G2/M phase was detected. With the increasing of concentration and extending of action time, the rate of apoptosis and necrosis of Hut-78 cells was gradually increased; 2.The expressions of hTERT, PML, PML-Ⅰ, PML-Ⅳand PML-Ⅴgenes in Hut-78 cells treated with Arsenic Trioxide in different concentrations for different action time were detected by RT-PCR.The results show that:(1) The expression of hTERT mRNA gradually decreased with the concentration of ATO increasing and acting time extending; (2) After treated with ATO in different concentrations after 48h, the transcription level of PML reached a maximum value, which was gradually decreased from 48h to 72h; (3) With prolonging treatment with 2umol/L and 10umol/L ATO respectively,the transcription level of PML-Ⅰwas gradually increased,When the concentration of ATO is 0 umol/L and 5 umol/L respectively,with prolonging treatment,the transcription level was gradually decreased from 24h to 48h,while that was gradually increased from 48h to 72h; (4) With ATO in different concentration,the transcription level of PML-Ⅳwas gradually increased from 24h to 48h with the acting time extending,while that was gradually decreased from 48h to 72h; (5) When the concentration of ATO is 0 umol/L and 2 umol/L respectively,with prolonging treatment,The expression of PML-Ⅴdid not change significantly.When the concentration of ATO was 5 umol/L and 10 umol/L respectively, with prolonging treatment, the transcription level was gradually increased; And at the dosage of 10 umol/L the increased trend of the transcription level was the most significant; 3. There was no correlation between the expression level of PML-IVand hTERT.
Conclusion:1.Arsenic trioxide can inhibit the proliferation of Hut-78 cells in a certain range of concentrations, which may be related to the decreasement in the transcription level of hTERT to some extent; 2.ATO can induce apoptosis of Hut-78 cells. And apoptosis occurs mainly in G2/M phase, which may be related to PML, PML-Ⅰand PML-Ⅳincreased and decreased the expression of telomerase activity; 3.ATO can induce apoptosis of Hut-78 cells, which is dependent on time and dose; 4.The expression of PML-Ⅴwas different with ATO in different concentrations, we speculated that the expression level of PML-Ⅴcould remarkably increase only in the strong stress caused by drug.
引文
1、周红升,孟凡义.造血干细胞移植治疗恶性淋巴瘤.实用医院临床杂志.2007,4(6)：16-19.
2、摘自沈志祥、石远凯等《淋巴瘤特殊问题诊治对策》.上海科学技术出版社.2009.1.
3、孙洪德,李元善,马玲,等.癌灵1号结合中医辩证治疗急性早幼粒白血病32例.中国中西医结合杂志.1992；12(3)；170.
4、张亭栋.开发砒霜.中国中西医结合杂志.2003；23(1)：65-66.
5、Doyle LA,Highsmith WE.Telomerase as diagnostic and therapeutic target for cancer.Expert Rev Anticancer Ther.2002;2:217-225.
6、Mokbel K.The evolving role of telomerase inhibitors in the treatment of cancer.Curr. Med. Res.Opin.2003;19:470-472.
7、Cosme-Blanco W,Chang S.Dual roles of telomere dysfunction in initiation and suppression of tumorigenesis.Exp Cell Res.2008;314:1973-1979.
8、Tauchi T,Shin-ya K,Sashida G,et al.Telomerase inhibition with a novel G-quadruplex-interactive agent,telomestatin:In vitro and in vivo studies in acute leukemia. Oncogene.2006;25:5719-5725.
9、Nakajima A,Tauchi T,Sashida G,et al.Telomerase inhibition enhances apoptosis in human acute leukemia cells:Possibility of antitelomerase therapy.Leukemia.2003;17:560-567.
10、Capraro V,Zane L,Poncet D,et al. Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp Hematol.2010VN.
11、Cohen SB,Graham ME,Lovrecz GO,et al.Protein composition of catalytically active human telomerase from immortal cells.Science.2007;315(5820):1850-3.
12、Nkamaura TM,Morin GB,Chapman KB,et al.Telomerase catalytic subunit homologs for from fission yeastandhuman.Science.1997;277(5328):955-959.
13、Kawahara R,Kinoshita H,Shirouzu K,et al.Analysis of hTERT mRNAexpression in biliary tract and pancreatic cancer.J Hepatobiliary Pancreat Surg.2007;14:189-193.
14、Udomchaiprasertkul W,Narong S,Kongsema M,et al.Detection of hTERT mRNAin gastrointestinal tract cancer specimens.Southeast Asian J Trop Med Public Health.2008;39(2):324-327.
15、Moriai M,Tsuji N,Kobayashi D,et al.Down-regulation of hTERT expression plays an important role in 15-deoxy-Δ12,14-prostaglandin J2-induced apoptosis in cancer cells.Int J Oncol.2009;34:1363-1372.
16、Xian-Ling GUO,Nan-Nan MA,Fei-Guo ZHOU,et al.Up-regulation of hTERT expression by low-dose cisplatin contributes to chemotherapy resistance in human hepatocellular cancer cells. Oncol Rep.2009;22:549-556.
17、Lagunoff M,Bechtel J,Venetsanakos E,et al.De novo infection and serial transmission of Kpaosi's sarcoma-associated herpesvirus in cultured endothelial cells. J Virol.2002;76(5):2440-2448.
18、Jarboe EA,Liaw KL,Thompson LC,et al.Anaylsis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma.Oneognee.2002;21(4):664-673.
19、Helder MN,Wisman GB,vander Zee GJ.Telomerase and telomeres:from basic biology to cancer treatment.Cancer Invest.2002;20(1):82-101.
20、Longfei Huo,Janice WS Tang,Junjian Huang,et al.Cancer Immunotherapy Targeting the Telomerase Reverse Transcriptase.Cell Mol Immunol.2006;3(1):1-9.
21、Bernardi R,Pandolfi PP.Structure,dynamics and functions of promyelocytic leukaemia nuclear bodies.Nat Rev Mol Cell Biol.2007;8(12):1006-1016.
22、Kumar PP,Bischof O,Purbey PK,et al. Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class Ⅰ locus.Nat Cell Biol. 2007;9(1):45-56
23、Salomoni P,Ferguson BJ,Wyllie AH,et al.New insights into the role of PML in tumour suppression.Cell Res.2008;18(6):622-640.
24、Condemine W, Takahashi Y,Le Bras M, et al. A nucleolar targeting signal in PML-Ⅰ addresses PML to nucleolar caps in stressed or senescent cells.J Cell Sci.2007;120(Pt 18):3219-3227.
25、Condemine W,Takahashi Y,Zhu J,et al.Characterization of endogenous human promyelocytic leukemia isoforms.Cancer Res.2006;66(12):6192-6198.
26、Luciani JJ,Depetris D,Usson Y,et al.PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase.J Cell Sci.2006;119 (Pt 12):2518-2531.
27、Block GJ,Eskiw CH,Dellaire G,et al.Transcriptional regulation is affected by subnuclear targeting of reporter plasmids to PML nuclear bodies.Mol Cell.Biol.2006;26(23):8814-8825.
28、Nguyen LA,Pandolfi PP,Aikawa Y,et al.Physical and functional link of the leukemia-associated factors AML1 and PML.Blood.2005;105(1):292-300.
29、Oh W,Ghim J,Lee EW,et al. PML-IV functions as a negative regulator of telomerase by interacting with TERT.J Cell Sci.2009;122 (Pt 15):2613-2622.
30、Yoshida H,Ichikawa H,Tagata Y,et al. PML-Retinoic Acid ReceptoraInhibits PMLIV Enhancement of PU.1-Induced C/EBP Expression in Myeloid Differentiation.Mol Cell Biol. 2007;27(16):5819-5834.
1、Savage KJ. Peripheral T-cell lymphomas. Blood Rev 2007; 21:201-16.
2、Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T-cell lymphomas, unspecified (or not otherwise specified):a review.Hematol Oncol.2008;26:8-20.
3、Kerbauy DM,Lesnikov V,Abbasi N,et al. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDS). Blood.2005;106(12):3917-25.
4、Wu X, Shi J, Wu Y,et al. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol Ther.2010;10(11):1201-14.
5、Lunghi Paolo, Giuliani Nicola, Mazzera Laura,et al. Targeting MEK/MAPK signal transduction module potentiatesATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood.2008; 112:2450-2462.
6、侯淑玲,张巧花.王军等.三氧化二砷治疗难治性恶性淋巴瘤近期疗效[J].中国肿瘤临床.2006.32(24)：1425-1426.
7、Duan XF, Wu YL, Xu HZ,et al. Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes. Chem Biol Interact.2010;183(1):222-30.
8、Yeh KY, Chang JW, Li YY.et al. Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis. Head Neck.2010 Aug 24.
9、Liu Y, Liang Y, Zheng T,et al. Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells. J Neurooncol.2011,Feb 17.
10、Tomuleasa C,Soritau O,Kacso G,et al.Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme. J BUON.2010,15(4):758-62.
11、Falnoga I,Slejkovec Z,Pucer A,et al.Arsenic metabolism in multiple myeloma and astrocytoma cells.Biol Trace Elem Res.2007;116(1):5-28.
12、Pettersson HM,Karlsson J,Pietras A,et al.Arsenic trioxide and neuroblastoma cytotoxicityJ Bioenerg Biomembr.2007;39 (1):35-41.
13、Subbarayan PR,Lima M,Ardalan B.Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectai carcinoma:a clinical experience.Acta Oncol.2007;46(4):557-561.
14、Han Y H,Kim S Z,Kim S H,et al.Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH, Cancer Lett.2008;270(1):40-55.
15、L Li,J D Zhang,Y P Liu,et al.The effect of arsenic trioxide (As2O3) on proliferation and cell cycle in gastric cancer cell line BGC823.J. Oncol.2008;14 (3):190-193.
16、Wu Y C,Yen W Y,Yih L H,et al.Requirement of a functional spindle checkpoint for arsenite-induced apoptosis.J. Cell. Biochem.2008;105 (3):678-687.
17、S Zhao, J Zhang, X Zhang,et al.Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status, Mol. Biol. Rep. 2008;35 (3):421-429.
18、S Zhao,Tsuchida T,Kawakami K,et al.Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status, Int. J. Oncol.2002;21(1):49-55.
19、Kircelli F,Akay C,Gazitt Y,et al.Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53:MAP kinase pathway is preferentially activated in cells expressing inactivated p53.Int. J. Oncol.2007;30 (4):993-1001.
20、Akay C,Gazitt Y.Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle.2003;2 (4):358-368.
21、Q Liu,Hilsenbeck S,Gazitt Y.Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest,activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.Blood.2003;101(10):4078-4087.
22、H S Huang, Z M Liu, L Ding,et al.Opposite effect of ERK1/2 and JNK on p53-independent p21WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity.J. Biomed. Sci.2006;13 (1):113-125.
23、Miller WH Jr,Shipper HM,Lee JS,et al.Mechanisms of action of arsenic trioxide.Cancer Res.2002;62(14):3893-903.
24、Yih LH,Hsueh SW,Luu WS,et al.Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells.Carcinogenesis.2005;26(1):53-63.
25、Gao F,Yi J,Yuan JQ,et al.The cell cycle relmed apoptotie susceptibility to arsenic trioxide is associated with the level ofreactive oxygen species.Cell Res.2004;14(1):81-5.
26、Lam HK, Li K, Chik KW,et al. Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.Int.J.Oncol.2005;27(2):537-45.
27、Wang DH,Wei HL,Zhao HS,et al.Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulming vital components in apoptotic pathway. Pharmacol Res.2005;52(5):376-85.
28、Xinquan Li,Xianzhong Ding,Thomas E. Arsenic Trioxide Induces Apoptosis in Pancreatic Cancer Cells viaChanges in Cell Cycle, Caspase Activation, and GADD Expression. Pancreas.2003;27(2):174-179.
29、Nakamura Y,Miyoshi N.Cell death induction by isothiocyanate and their underlying molecular mechanisms.Biofactors.2006;26(2):123-34.
30、Houtgraaf JH,Versmissen J,van der Giessen WJ.A concise review of DNA darnage checkpoints and repair in mammalian cells.Cardiovasc Revasc Med.2006;7(3):165-72.
31、凌跃新,艾志龙,锁涛等.三氧化二砷抑制人胆囊癌细胞生长及对细胞周期蛋白D1表达影响.中国癌症杂志.2007；7(II)：867-890.
32、丁新民,保庭毅,杨增悦等.三氧化二砷对前列腺癌PC.3细胞周期的阻滞作用[J].中国临床康复.2005；9(2)：174-175.
33、Vogelstein B,Lane D,Levine A J.Surfing the p53 network.Nature.2000;408307-310.
34、Vousden K H,Lane D P. p53 in health and disease.Nat. Rev. Mol.Cell Biol.2007;8 275-283.
35、Joe Y,Jeong JH,Yang S,et al.ATR,PML,andCHK2 play a role in arsenic trioxideinduced apoptosis.J. Biol. Chem.2006; 281 (39):28764-28771.
36、Louria-Hayon I,Grossman T,Sionov R V,et al.The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.J. Biol. Chem.2003;278 (35):33134-33141.
37、Park JW,Choi YJ,Jang MA,et al.Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylationin promonocytic U937 cells.Biochem. Biophys. Res. Commun.2001;286:726-734.
38、Taylor BF,McNeely SC,Miller HL,et al.p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1, J. Pharmacol. Exp. Ther.2006;318 (1):142-151.
39、马学斌,谷志远,宋海静等.三氧化二砷对Hela细胞hTERT-mRNA表达的调节和对端粒酶活 性的影响.军医进修学院学报.2004；25(1)：26-28.
40、梅树江,尹家俊,王晓梅.As203对人胃癌BGC-823细胞端粒酶的影响.肿瘤防治研究.2007；34(12)：927-931.
41、Jiuli Zhang,Jinlong Li,Shiwen Xu.Research Advances of Mechanism on Apoptosis of Tumor Cells Induced by Arsenic Trioxide.Chinese Agricultural Science Bulletin.2007.23(2).
42、Li W, Li L, Liu Z,et al. Expression of the full-length telomerase reverse transcriptase (hTERT) transcript in both malignant and normal gastric tissues.Cancer Lett.2008;260:28-36.
43、Saleh S,Lam AK,He YH.Real-time PCR quantification of human telomerase reverse transcfiptase(hTERT)in colorectalcancer.Pathology.2008;40(1):25-30.
44、Branca M, Giorgi C, Ciotti M,et al. Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus, virus persistence, or disease outcome in cervical cancer. Diagn Cytopathol. 2006;34(11):739-48.
45、Nagel I,Szczepanowski M,Martin-Subero JI,et al.Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. Blood.2010;116(8):1317-20
46、Gessner A,Thomas M,Castro PG,et al.Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia.2010;24(10):1751-9.
47、Kurvinen K,Syrjanen S,Johansson B.Long-term suppression of telomerase expression in HeLa cell clones, transfected with an expression vector carrying siRNA targeting hTERT mRNA.Int J Oncol.2006;29(1):279-88
48、Wang R, Lin F, Wang X,et al.The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression.Cancer Biol Ther.2007;6(8):1295-301.
1、Koken MHM,Linares-Cruz G,Quignon F,et al.The PML growth-suppressor has an altered expression in human oncogenesis.Oncogene.1995;10:1315-24.
2、Terris B,Baldin V,Dubois S,et al.PML nuclear bodies are general targets for inflammation and cell proliferation.Cancer Res.1995;55:1590-7.
3、Gurrieri C, Capodieci P, Bernardi R, et al.Loss.of the tumor suppressor PML in human cancers of multiple histologic origins.J Natl Cancer Inst.2004;96:269-279.
4、Gambacorta M,Flenghi L,Fagioli M,et al.Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues.Am J Pathol.1996; 149:2023-2035.
5、Lee HE,Jee CD,Kim MA,et al.Loss of promyelocytic leukemia protein in human gastric cancers.Cancer Lett.2007;247:103-109.
6、Zhang P,Chin W,Chow LT,et al.Lack of expression for the suppressor PML in human small cell lung carcinoma.Int J Cancer.2000;85:599-605.
7、Vincenzi B,Perrone G,Santini D,et al. PML down-regulation in soft tissue sarcomas.J Cell Physiol.2010;224(3):644-8.
8、Paul RH,Laidlaw DH,Tate DF,et al.Neuropsychological and neuroimaging outcome of HIV-associated progressive multifocal leukoencephalopathy in the era of antiretroviral therapy.J.Integr.Neurosci.2007;6:191-203.
9、Vincenzi B,Santini D,Perrone G,et al. Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients.2009;Annals of Oncology.20:78-83,
10、Ito K, Bernardi R, Morotti A,et al. PML targeting eradicates quiescent leukaemia-initiating cells.Nature,2008;453:1072-8.
11、Trecca D,Longo L,Biondi A,et al.Analysis of p53gene mutations in acute myeloid leukemia.Am J Hematol.1994;46:304-9.
12、Li Y,Guessous F,Kwon S,et al.PTEN has tumorpromoting properties in the setting of gain-of-function p53 mutations.Cancer Res.2008;68:1723-31.
13、Haupt S, Di Agostino S,Mizrahi I,et al. Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53.CancerRes.2009;69:(11):4818-4825.
14、Reed J C,Bischoff J R. BIRinging chromosomes through cell division--and survivin'the experience.Cell.2000;102(5):545-548.
15、Pise-Masison CA,Radonovich M,Dohoney K,et al.Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood.2009;113:4016-26.
16、Ito T,Shirak K,Sugimoto K,et al.Survivin promotes cell pmliferation in human hepatocelluarcarcinoma.Hepatology.2000;31(5):1080-1085.
17、Scheper MA,Nikitakis NG,Chaisuparat R,et al.Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma.Neoplasia.2007;9(3):192-199.
18、Diaz N,Minton S,Cox C,et al.Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res.2006;12(1):20-28.
19、王智明,刘芳,管新明等.凋亡抑制蛋白survivin在舌鳞癌中的表达及临床意义.上海口腔医学.2007；16(2)：157-160.
20、Li F,Ambrosini G,Chu E Y,et al.Control of apoptosis and mitotic spindle checkpoint by survivin.Nature.1998;396(6711):580-584.
21、ZX Xu,RX Zhao,T Ding,et al.Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression.J Biol Chem.2004;279:1838-44.
22、Hubackova S, Novakova Z, Krejcikova K,et al.PML promotes senescence via JAK/STAT signaling.Cell Cycle.2010;9(15):3085-99.
23、Condemine W,Takahashi Y,Zhu J, et al.Characterization of endogenous human promyelocytic leukemia isoforms.Cancer Res.2006;66(12):6192-6198.
24、Luciani JJ,Depetris D,Usson Y,et al. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase.J Cell Sci.2006;119 (Pt 12):2518-2531.
25、Buschbeck M,Uribesalgo I,Ledl A,et al.PML4 induces differentiation by Myc destabilization. Oncogene.2007;26:3415-3422.
26、Bischof O,Kirsh O,Pearson M,et al.Deconstructing PML-induced premature senescence.EMBO J.2002;21(13):3358-3369.
27、Quignon F,De Bels F,Koken M, et al.PML induces a novel caspase independent death process. Nat Genet.1998;20:259-65.
28、Oh W,Ghim J,Lee EW,et al.PML-IV functions as a negative regulator of telomerase by interacting with TERT.J Cell Sci.2009;122 (Pt 15):2613-2622.
1、Lang M,Jegou T, Chung I,et al. Three-dimensional organization of promyelocytic leukemia nuclear bodies.J Cell Sci.2010;123(Pt 3):392-400.
2、Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies.Nat Rev Mol Cell Biol.2007;8(12):1006-1016.
3、Kumar PP,Bischof O, Purbey PK,et al. Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus.Nat Cell Biol. 2007;9(1):45-56.
4、Salomoni P, Ferguson BJ, Wyllie AH, et al.New insights into the role of PML in tumour suppression.Cell Res.2008; 18(6)622-640.
5、Condemine W, Takahashi Y, Zhu J, et al. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res.2006;66(12):6192-6198.
6、Condemine W, Takahashi Y, Le Bras M, et al. A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells.J Cell Sci.2007;120 (Pt 18):3219-3227.
7、Weidtkamp-Peters S, Lenser T, Negorev D, et al.Dynamics of component exchange at PML nuclear bodies.J Cell Sci.2008;121(Pt 16):2731-2743.
8、Luciani JJ,Depetris D,Usson Y,et al. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase.J Cell Sci.2006; 119 (Pt 12):2518-2531.
9、Block GJ,Eskiw CH,Dellaire G,et al.Transcriptional regulation is affected by subnuclear targeting of reporter plasmids to PML nuclear bodies.Mol Cell Biol.2006;26(23):8814-8825.
10、Nguyen LA, Pandolfi PP, Aikawa Y, et al. Physical and functional link of the leukemia-associated factors AML1 and PML.Blood.2005;105(1):292-300.
11、Hoppe A, Beech SJ, Dimmock J, et al. Interaction of the Adenovirus Type 5 E4 Orf3 Protein with Promyelocytic Leukemia Protein Isoform II Is Required for ND10 Disruption.J Virol.2006;80(Pt 6):3042-3049.
12、Leppard KN, Emmott E, Cortese MS,et al. Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence in PML isoform Ⅱ that is predicted as a protein interaction site by bioinformatic analysis. J Gen Virol.2009;90(Pt 1):95-104.
13、Xu ZX, Zou WX, Lin P, et al. A role for PML3 in centrosome duplication and genome stability.Mol Cell.2005;17(5):721-732.
14、Fischle W.Tip60-ing the balance in DSB repair. Nat Cell Biol.2009;11(11):1279-1281.
15、Sun Y, Jiang X, Price BD.Tip60:connecting chromatin to DNA damage signaling.Cell Cycle.2010;9(5):930-936.
16、Wu Q, Hu H, Lan J, et al.PML3 Orchestrates the Nuclear Dynamics and Function of TIP60.J Biol Chem.2009;284(13):8747-8759.
17、Jiang WQ, Zhong ZH, Henson JD,et al.Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference.Oncogene. 2007;26(32):4635-4647.
18、Fan Q, Zhang F, Barrett B,et al.Andreassen.A role for monoubiquitinated FANCD2 at telomeres in ALT cells.Nucleic Acids Res.2009;37(6):1740-1754.
19、Potts PR, Yu H.The SMC5/6 complex maintains telomere length in ALT cancer cells through sumoylation of telomere-binding proteins.Nat Struct Mol Biol.2007;14(7):581-590.
20、Yu J, Lan J, Wang C, et al. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells.Cancer Lett.2010;291(2):177-186.
21、Oh W, Ghim J, Lee EW, et al. PML-IV functions as a negative regulator of telomerase by interacting with TERT.J Cell Sci.2009;122 (Pt 15):2613-2622.
22、Janer A, Martin E, Muriel MP, et al. PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins.J Cell Biol.2006;174(1):165-176.
23、Yoshida H, Ichikawa H, Tagata Y,et al. PML-Retinoic Acid Receptora Inhibits PMLIV Enhancement of PU.1-Induced C/EBP Expression in Myeloid Differentiation.Mol Cell Biol.2007;27(16):5819-5834.
24、Li W, Wang G, Zhang H, et al.Differential suppressive effect of promyelocytic leukemia protein on the replication of different subtypes/strains of influenza A virus.Biochem Biophys Res Commun.2009;389(1):84-89.
2、摘自沈志祥、石远凯等《淋巴瘤特殊问题诊治对策》.上海科学技术出版社.2009.1.
3、孙洪德,李元善,马玲,等.癌灵1号结合中医辩证治疗急性早幼粒白血病32例.中国中西医结合杂志.1992；12(3)；170.
4、张亭栋.开发砒霜.中国中西医结合杂志.2003；23(1)：65-66.
5、Doyle LA,Highsmith WE.Telomerase as diagnostic and therapeutic target for cancer.Expert Rev Anticancer Ther.2002;2:217-225.
6、Mokbel K.The evolving role of telomerase inhibitors in the treatment of cancer.Curr. Med. Res.Opin.2003;19:470-472.
7、Cosme-Blanco W,Chang S.Dual roles of telomere dysfunction in initiation and suppression of tumorigenesis.Exp Cell Res.2008;314:1973-1979.
8、Tauchi T,Shin-ya K,Sashida G,et al.Telomerase inhibition with a novel G-quadruplex-interactive agent,telomestatin:In vitro and in vivo studies in acute leukemia. Oncogene.2006;25:5719-5725.
9、Nakajima A,Tauchi T,Sashida G,et al.Telomerase inhibition enhances apoptosis in human acute leukemia cells:Possibility of antitelomerase therapy.Leukemia.2003;17:560-567.
10、Capraro V,Zane L,Poncet D,et al. Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp Hematol.2010VN.
11、Cohen SB,Graham ME,Lovrecz GO,et al.Protein composition of catalytically active human telomerase from immortal cells.Science.2007;315(5820):1850-3.
12、Nkamaura TM,Morin GB,Chapman KB,et al.Telomerase catalytic subunit homologs for from fission yeastandhuman.Science.1997;277(5328):955-959.
13、Kawahara R,Kinoshita H,Shirouzu K,et al.Analysis of hTERT mRNAexpression in biliary tract and pancreatic cancer.J Hepatobiliary Pancreat Surg.2007;14:189-193.
14、Udomchaiprasertkul W,Narong S,Kongsema M,et al.Detection of hTERT mRNAin gastrointestinal tract cancer specimens.Southeast Asian J Trop Med Public Health.2008;39(2):324-327.
15、Moriai M,Tsuji N,Kobayashi D,et al.Down-regulation of hTERT expression plays an important role in 15-deoxy-Δ12,14-prostaglandin J2-induced apoptosis in cancer cells.Int J Oncol.2009;34:1363-1372.
16、Xian-Ling GUO,Nan-Nan MA,Fei-Guo ZHOU,et al.Up-regulation of hTERT expression by low-dose cisplatin contributes to chemotherapy resistance in human hepatocellular cancer cells. Oncol Rep.2009;22:549-556.
17、Lagunoff M,Bechtel J,Venetsanakos E,et al.De novo infection and serial transmission of Kpaosi's sarcoma-associated herpesvirus in cultured endothelial cells. J Virol.2002;76(5):2440-2448.
18、Jarboe EA,Liaw KL,Thompson LC,et al.Anaylsis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma.Oneognee.2002;21(4):664-673.
19、Helder MN,Wisman GB,vander Zee GJ.Telomerase and telomeres:from basic biology to cancer treatment.Cancer Invest.2002;20(1):82-101.
20、Longfei Huo,Janice WS Tang,Junjian Huang,et al.Cancer Immunotherapy Targeting the Telomerase Reverse Transcriptase.Cell Mol Immunol.2006;3(1):1-9.
21、Bernardi R,Pandolfi PP.Structure,dynamics and functions of promyelocytic leukaemia nuclear bodies.Nat Rev Mol Cell Biol.2007;8(12):1006-1016.
22、Kumar PP,Bischof O,Purbey PK,et al. Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class Ⅰ locus.Nat Cell Biol. 2007;9(1):45-56
23、Salomoni P,Ferguson BJ,Wyllie AH,et al.New insights into the role of PML in tumour suppression.Cell Res.2008;18(6):622-640.
24、Condemine W, Takahashi Y,Le Bras M, et al. A nucleolar targeting signal in PML-Ⅰ addresses PML to nucleolar caps in stressed or senescent cells.J Cell Sci.2007;120(Pt 18):3219-3227.
25、Condemine W,Takahashi Y,Zhu J,et al.Characterization of endogenous human promyelocytic leukemia isoforms.Cancer Res.2006;66(12):6192-6198.
26、Luciani JJ,Depetris D,Usson Y,et al.PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase.J Cell Sci.2006;119 (Pt 12):2518-2531.
27、Block GJ,Eskiw CH,Dellaire G,et al.Transcriptional regulation is affected by subnuclear targeting of reporter plasmids to PML nuclear bodies.Mol Cell.Biol.2006;26(23):8814-8825.
28、Nguyen LA,Pandolfi PP,Aikawa Y,et al.Physical and functional link of the leukemia-associated factors AML1 and PML.Blood.2005;105(1):292-300.
29、Oh W,Ghim J,Lee EW,et al. PML-IV functions as a negative regulator of telomerase by interacting with TERT.J Cell Sci.2009;122 (Pt 15):2613-2622.
30、Yoshida H,Ichikawa H,Tagata Y,et al. PML-Retinoic Acid ReceptoraInhibits PMLIV Enhancement of PU.1-Induced C/EBP Expression in Myeloid Differentiation.Mol Cell Biol. 2007;27(16):5819-5834.
1、Savage KJ. Peripheral T-cell lymphomas. Blood Rev 2007; 21:201-16.
2、Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T-cell lymphomas, unspecified (or not otherwise specified):a review.Hematol Oncol.2008;26:8-20.
3、Kerbauy DM,Lesnikov V,Abbasi N,et al. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDS). Blood.2005;106(12):3917-25.
4、Wu X, Shi J, Wu Y,et al. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol Ther.2010;10(11):1201-14.
5、Lunghi Paolo, Giuliani Nicola, Mazzera Laura,et al. Targeting MEK/MAPK signal transduction module potentiatesATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood.2008; 112:2450-2462.
6、侯淑玲,张巧花.王军等.三氧化二砷治疗难治性恶性淋巴瘤近期疗效[J].中国肿瘤临床.2006.32(24)：1425-1426.
7、Duan XF, Wu YL, Xu HZ,et al. Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes. Chem Biol Interact.2010;183(1):222-30.
8、Yeh KY, Chang JW, Li YY.et al. Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis. Head Neck.2010 Aug 24.
9、Liu Y, Liang Y, Zheng T,et al. Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells. J Neurooncol.2011,Feb 17.
10、Tomuleasa C,Soritau O,Kacso G,et al.Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme. J BUON.2010,15(4):758-62.
11、Falnoga I,Slejkovec Z,Pucer A,et al.Arsenic metabolism in multiple myeloma and astrocytoma cells.Biol Trace Elem Res.2007;116(1):5-28.
12、Pettersson HM,Karlsson J,Pietras A,et al.Arsenic trioxide and neuroblastoma cytotoxicityJ Bioenerg Biomembr.2007;39 (1):35-41.
13、Subbarayan PR,Lima M,Ardalan B.Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectai carcinoma:a clinical experience.Acta Oncol.2007;46(4):557-561.
14、Han Y H,Kim S Z,Kim S H,et al.Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH, Cancer Lett.2008;270(1):40-55.
15、L Li,J D Zhang,Y P Liu,et al.The effect of arsenic trioxide (As2O3) on proliferation and cell cycle in gastric cancer cell line BGC823.J. Oncol.2008;14 (3):190-193.
16、Wu Y C,Yen W Y,Yih L H,et al.Requirement of a functional spindle checkpoint for arsenite-induced apoptosis.J. Cell. Biochem.2008;105 (3):678-687.
17、S Zhao, J Zhang, X Zhang,et al.Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status, Mol. Biol. Rep. 2008;35 (3):421-429.
18、S Zhao,Tsuchida T,Kawakami K,et al.Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status, Int. J. Oncol.2002;21(1):49-55.
19、Kircelli F,Akay C,Gazitt Y,et al.Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53:MAP kinase pathway is preferentially activated in cells expressing inactivated p53.Int. J. Oncol.2007;30 (4):993-1001.
20、Akay C,Gazitt Y.Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle.2003;2 (4):358-368.
21、Q Liu,Hilsenbeck S,Gazitt Y.Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest,activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.Blood.2003;101(10):4078-4087.
22、H S Huang, Z M Liu, L Ding,et al.Opposite effect of ERK1/2 and JNK on p53-independent p21WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity.J. Biomed. Sci.2006;13 (1):113-125.
23、Miller WH Jr,Shipper HM,Lee JS,et al.Mechanisms of action of arsenic trioxide.Cancer Res.2002;62(14):3893-903.
24、Yih LH,Hsueh SW,Luu WS,et al.Arsenite induces prominent mitotic arrest via inhibition of G2 checkpoint activation in CGL-2 cells.Carcinogenesis.2005;26(1):53-63.
25、Gao F,Yi J,Yuan JQ,et al.The cell cycle relmed apoptotie susceptibility to arsenic trioxide is associated with the level ofreactive oxygen species.Cell Res.2004;14(1):81-5.
26、Lam HK, Li K, Chik KW,et al. Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.Int.J.Oncol.2005;27(2):537-45.
27、Wang DH,Wei HL,Zhao HS,et al.Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulming vital components in apoptotic pathway. Pharmacol Res.2005;52(5):376-85.
28、Xinquan Li,Xianzhong Ding,Thomas E. Arsenic Trioxide Induces Apoptosis in Pancreatic Cancer Cells viaChanges in Cell Cycle, Caspase Activation, and GADD Expression. Pancreas.2003;27(2):174-179.
29、Nakamura Y,Miyoshi N.Cell death induction by isothiocyanate and their underlying molecular mechanisms.Biofactors.2006;26(2):123-34.
30、Houtgraaf JH,Versmissen J,van der Giessen WJ.A concise review of DNA darnage checkpoints and repair in mammalian cells.Cardiovasc Revasc Med.2006;7(3):165-72.
31、凌跃新,艾志龙,锁涛等.三氧化二砷抑制人胆囊癌细胞生长及对细胞周期蛋白D1表达影响.中国癌症杂志.2007；7(II)：867-890.
32、丁新民,保庭毅,杨增悦等.三氧化二砷对前列腺癌PC.3细胞周期的阻滞作用[J].中国临床康复.2005；9(2)：174-175.
33、Vogelstein B,Lane D,Levine A J.Surfing the p53 network.Nature.2000;408307-310.
34、Vousden K H,Lane D P. p53 in health and disease.Nat. Rev. Mol.Cell Biol.2007;8 275-283.
35、Joe Y,Jeong JH,Yang S,et al.ATR,PML,andCHK2 play a role in arsenic trioxideinduced apoptosis.J. Biol. Chem.2006; 281 (39):28764-28771.
36、Louria-Hayon I,Grossman T,Sionov R V,et al.The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation.J. Biol. Chem.2003;278 (35):33134-33141.
37、Park JW,Choi YJ,Jang MA,et al.Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylationin promonocytic U937 cells.Biochem. Biophys. Res. Commun.2001;286:726-734.
38、Taylor BF,McNeely SC,Miller HL,et al.p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1, J. Pharmacol. Exp. Ther.2006;318 (1):142-151.
39、马学斌,谷志远,宋海静等.三氧化二砷对Hela细胞hTERT-mRNA表达的调节和对端粒酶活 性的影响.军医进修学院学报.2004；25(1)：26-28.
40、梅树江,尹家俊,王晓梅.As203对人胃癌BGC-823细胞端粒酶的影响.肿瘤防治研究.2007；34(12)：927-931.
41、Jiuli Zhang,Jinlong Li,Shiwen Xu.Research Advances of Mechanism on Apoptosis of Tumor Cells Induced by Arsenic Trioxide.Chinese Agricultural Science Bulletin.2007.23(2).
42、Li W, Li L, Liu Z,et al. Expression of the full-length telomerase reverse transcriptase (hTERT) transcript in both malignant and normal gastric tissues.Cancer Lett.2008;260:28-36.
43、Saleh S,Lam AK,He YH.Real-time PCR quantification of human telomerase reverse transcfiptase(hTERT)in colorectalcancer.Pathology.2008;40(1):25-30.
44、Branca M, Giorgi C, Ciotti M,et al. Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus, virus persistence, or disease outcome in cervical cancer. Diagn Cytopathol. 2006;34(11):739-48.
45、Nagel I,Szczepanowski M,Martin-Subero JI,et al.Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. Blood.2010;116(8):1317-20
46、Gessner A,Thomas M,Castro PG,et al.Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia.2010;24(10):1751-9.
47、Kurvinen K,Syrjanen S,Johansson B.Long-term suppression of telomerase expression in HeLa cell clones, transfected with an expression vector carrying siRNA targeting hTERT mRNA.Int J Oncol.2006;29(1):279-88
48、Wang R, Lin F, Wang X,et al.The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression.Cancer Biol Ther.2007;6(8):1295-301.
1、Koken MHM,Linares-Cruz G,Quignon F,et al.The PML growth-suppressor has an altered expression in human oncogenesis.Oncogene.1995;10:1315-24.
2、Terris B,Baldin V,Dubois S,et al.PML nuclear bodies are general targets for inflammation and cell proliferation.Cancer Res.1995;55:1590-7.
3、Gurrieri C, Capodieci P, Bernardi R, et al.Loss.of the tumor suppressor PML in human cancers of multiple histologic origins.J Natl Cancer Inst.2004;96:269-279.
4、Gambacorta M,Flenghi L,Fagioli M,et al.Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues.Am J Pathol.1996; 149:2023-2035.
5、Lee HE,Jee CD,Kim MA,et al.Loss of promyelocytic leukemia protein in human gastric cancers.Cancer Lett.2007;247:103-109.
6、Zhang P,Chin W,Chow LT,et al.Lack of expression for the suppressor PML in human small cell lung carcinoma.Int J Cancer.2000;85:599-605.
7、Vincenzi B,Perrone G,Santini D,et al. PML down-regulation in soft tissue sarcomas.J Cell Physiol.2010;224(3):644-8.
8、Paul RH,Laidlaw DH,Tate DF,et al.Neuropsychological and neuroimaging outcome of HIV-associated progressive multifocal leukoencephalopathy in the era of antiretroviral therapy.J.Integr.Neurosci.2007;6:191-203.
9、Vincenzi B,Santini D,Perrone G,et al. Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients.2009;Annals of Oncology.20:78-83,
10、Ito K, Bernardi R, Morotti A,et al. PML targeting eradicates quiescent leukaemia-initiating cells.Nature,2008;453:1072-8.
11、Trecca D,Longo L,Biondi A,et al.Analysis of p53gene mutations in acute myeloid leukemia.Am J Hematol.1994;46:304-9.
12、Li Y,Guessous F,Kwon S,et al.PTEN has tumorpromoting properties in the setting of gain-of-function p53 mutations.Cancer Res.2008;68:1723-31.
13、Haupt S, Di Agostino S,Mizrahi I,et al. Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53.CancerRes.2009;69:(11):4818-4825.
14、Reed J C,Bischoff J R. BIRinging chromosomes through cell division--and survivin'the experience.Cell.2000;102(5):545-548.
15、Pise-Masison CA,Radonovich M,Dohoney K,et al.Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood.2009;113:4016-26.
16、Ito T,Shirak K,Sugimoto K,et al.Survivin promotes cell pmliferation in human hepatocelluarcarcinoma.Hepatology.2000;31(5):1080-1085.
17、Scheper MA,Nikitakis NG,Chaisuparat R,et al.Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma.Neoplasia.2007;9(3):192-199.
18、Diaz N,Minton S,Cox C,et al.Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res.2006;12(1):20-28.
19、王智明,刘芳,管新明等.凋亡抑制蛋白survivin在舌鳞癌中的表达及临床意义.上海口腔医学.2007；16(2)：157-160.
20、Li F,Ambrosini G,Chu E Y,et al.Control of apoptosis and mitotic spindle checkpoint by survivin.Nature.1998;396(6711):580-584.
21、ZX Xu,RX Zhao,T Ding,et al.Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression.J Biol Chem.2004;279:1838-44.
22、Hubackova S, Novakova Z, Krejcikova K,et al.PML promotes senescence via JAK/STAT signaling.Cell Cycle.2010;9(15):3085-99.
23、Condemine W,Takahashi Y,Zhu J, et al.Characterization of endogenous human promyelocytic leukemia isoforms.Cancer Res.2006;66(12):6192-6198.
24、Luciani JJ,Depetris D,Usson Y,et al. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase.J Cell Sci.2006;119 (Pt 12):2518-2531.
25、Buschbeck M,Uribesalgo I,Ledl A,et al.PML4 induces differentiation by Myc destabilization. Oncogene.2007;26:3415-3422.
26、Bischof O,Kirsh O,Pearson M,et al.Deconstructing PML-induced premature senescence.EMBO J.2002;21(13):3358-3369.
27、Quignon F,De Bels F,Koken M, et al.PML induces a novel caspase independent death process. Nat Genet.1998;20:259-65.
28、Oh W,Ghim J,Lee EW,et al.PML-IV functions as a negative regulator of telomerase by interacting with TERT.J Cell Sci.2009;122 (Pt 15):2613-2622.
1、Lang M,Jegou T, Chung I,et al. Three-dimensional organization of promyelocytic leukemia nuclear bodies.J Cell Sci.2010;123(Pt 3):392-400.
2、Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies.Nat Rev Mol Cell Biol.2007;8(12):1006-1016.
3、Kumar PP,Bischof O, Purbey PK,et al. Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus.Nat Cell Biol. 2007;9(1):45-56.
4、Salomoni P, Ferguson BJ, Wyllie AH, et al.New insights into the role of PML in tumour suppression.Cell Res.2008; 18(6)622-640.
5、Condemine W, Takahashi Y, Zhu J, et al. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res.2006;66(12):6192-6198.
6、Condemine W, Takahashi Y, Le Bras M, et al. A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells.J Cell Sci.2007;120 (Pt 18):3219-3227.
7、Weidtkamp-Peters S, Lenser T, Negorev D, et al.Dynamics of component exchange at PML nuclear bodies.J Cell Sci.2008;121(Pt 16):2731-2743.
8、Luciani JJ,Depetris D,Usson Y,et al. PML nuclear bodies are highly organised DNA-protein structures with a function in heterochromatin remodelling at the G2 phase.J Cell Sci.2006; 119 (Pt 12):2518-2531.
9、Block GJ,Eskiw CH,Dellaire G,et al.Transcriptional regulation is affected by subnuclear targeting of reporter plasmids to PML nuclear bodies.Mol Cell Biol.2006;26(23):8814-8825.
10、Nguyen LA, Pandolfi PP, Aikawa Y, et al. Physical and functional link of the leukemia-associated factors AML1 and PML.Blood.2005;105(1):292-300.
11、Hoppe A, Beech SJ, Dimmock J, et al. Interaction of the Adenovirus Type 5 E4 Orf3 Protein with Promyelocytic Leukemia Protein Isoform II Is Required for ND10 Disruption.J Virol.2006;80(Pt 6):3042-3049.
12、Leppard KN, Emmott E, Cortese MS,et al. Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence in PML isoform Ⅱ that is predicted as a protein interaction site by bioinformatic analysis. J Gen Virol.2009;90(Pt 1):95-104.
13、Xu ZX, Zou WX, Lin P, et al. A role for PML3 in centrosome duplication and genome stability.Mol Cell.2005;17(5):721-732.
14、Fischle W.Tip60-ing the balance in DSB repair. Nat Cell Biol.2009;11(11):1279-1281.
15、Sun Y, Jiang X, Price BD.Tip60:connecting chromatin to DNA damage signaling.Cell Cycle.2010;9(5):930-936.
16、Wu Q, Hu H, Lan J, et al.PML3 Orchestrates the Nuclear Dynamics and Function of TIP60.J Biol Chem.2009;284(13):8747-8759.
17、Jiang WQ, Zhong ZH, Henson JD,et al.Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference.Oncogene. 2007;26(32):4635-4647.
18、Fan Q, Zhang F, Barrett B,et al.Andreassen.A role for monoubiquitinated FANCD2 at telomeres in ALT cells.Nucleic Acids Res.2009;37(6):1740-1754.
19、Potts PR, Yu H.The SMC5/6 complex maintains telomere length in ALT cancer cells through sumoylation of telomere-binding proteins.Nat Struct Mol Biol.2007;14(7):581-590.
20、Yu J, Lan J, Wang C, et al. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells.Cancer Lett.2010;291(2):177-186.
21、Oh W, Ghim J, Lee EW, et al. PML-IV functions as a negative regulator of telomerase by interacting with TERT.J Cell Sci.2009;122 (Pt 15):2613-2622.
22、Janer A, Martin E, Muriel MP, et al. PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins.J Cell Biol.2006;174(1):165-176.
23、Yoshida H, Ichikawa H, Tagata Y,et al. PML-Retinoic Acid Receptora Inhibits PMLIV Enhancement of PU.1-Induced C/EBP Expression in Myeloid Differentiation.Mol Cell Biol.2007;27(16):5819-5834.
24、Li W, Wang G, Zhang H, et al.Differential suppressive effect of promyelocytic leukemia protein on the replication of different subtypes/strains of influenza A virus.Biochem Biophys Res Commun.2009;389(1):84-89.